The effect of ruxolitinib on progeria phenotypes is a phenocopy of that observed in Pla2r1 knockout mice, that is, reduced numbers of rib fractures, increased BMC, and improved grip strength (Griveau et al., 2018). Here, PLA2R1 is linked to progeroid syndrome.